Review article: current gaps and opportunities in HBV prevention, testing and linkage to care in the United States—a call for action
Yee Hui Yeo,Mindie H. Nguyen +1 more
TLDR
A comprehensive review of current HBV testing and care gaps is needed to help formulate solutions and opportunities for action to achieve elimination goal by 2030.Abstract:
Background The World Health Organization (WHO) has set an elimination goal for hepatitis B virus (HBV) by 2030, so a comprehensive review of current HBV testing and care gaps are needed to help formulate solutions and opportunities for action. Aims To summarise current gaps and barriers, and to propose solutions for HBV prevention, testing and linkage to care in the United States METHODS: Relevant guidelines and studies were reviewed including a systematic review of HCC surveillance adherence. Results A total of 64.5 million (95% CI, 61.3-67.5) high-risk US adults had no evidence of HBV immunity. Only 18.6% (95% CI, 13.5-29.9) of privately insured patients with HBV infection have been diagnosed. Among those with known HBV infection, linkage to care rate (33.3%-57%) was poor and the adherence to guidelines regarding anti-viral therapy (30.66% [95% CI, 30.28-31.03]) and HCC surveillance (8%-87%, from a systematic review) were poor with even more concerning data for care and treatment retention. The causes are complex and include lack of access to medical care, lack of physician knowledge, lack of patient health literacy and awareness, linguistic and cultural barriers and fear of stigma. Conclusions A 'scale-up' effort is needed to optimise the care continuum to achieve the WHO 2030 targets. As targeted screening policy has leftover 80% of patients undiagnosed, we advocate for universal screening which can help to remove barriers regarding stigma. More active and system level interventions are also needed to improve linkage to care for patients with HBV infection.read more
Citations
More filters
Journal ArticleDOI
CRISPR/Cas12-Based Ultra-Sensitive and Specific Point-of-Care Detection of HBV
Ronghua Ding,Jinzhao Long,Mingzhu Yuan,Xue Zheng,Yue Shen,Yuefei Jin,Haiyan Yang,Hao Li,Shuaiyin Chen,Guangcai Duan +9 more
TL;DR: In this paper, a point-of-care test for hepatitis B based on LAMP-Cas12a has been proposed to solve the problem of sample nucleic acid extraction in 10 min, and visualization of the results is presented by both a fluorescent readout and by lateral flow test strips.
Journal ArticleDOI
Substantial gaps in evaluation and treatment of patients with hepatitis B in the US.
Qing Ye,Leslie Y. Kam,Yee Hui Yeo,Yee Hui Yeo,Nolan Dang,Daniel Q. Huang,Daniel Q. Huang,Ramsey Cheung,Ramsey Cheung,Mindie H. Nguyen +9 more
TL;DR: In this article, the proportion of patients with chronic HBV infection who received adequate evaluation, were treatment eligible, and received antiviral treatment using a large, nationwide cohort was determined.
Journal ArticleDOI
Treatment eligibility in hepatitis B: a call for better linkage to optimal care.
Daniel Q. Huang,Mindie H. Nguyen +1 more
Journal ArticleDOI
Perspectives on the Underlying Etiology of HCC and Its Effects on Treatment Outcomes
Takanori Ito,M. Hong Nguyen +1 more
TL;DR: In this paper , the authors provide an overview of the epidemiologic trends in the etiologies of HCC, and the progress of treatments for each etiology and the impact on outcome in the patients with HCC.
Journal ArticleDOI
Perspectives on the Underlying Etiology of HCC and Its Effects on Treatment Outcomes
TL;DR: In this article , the authors provide an overview of the epidemiologic trends in the etiologies of HCC, and the progress of treatments for each etiology and the impact on outcome in the patients with HCC.
References
More filters
Journal ArticleDOI
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.
Pietro Lampertico,Kosh Agarwal,Thomas Berg,Maria Buti,Harry L.A. Janssen,George V. Papatheodoridis,Fabien Zoulim,Frank Tacke +7 more
TL;DR: This Clinical Practice Guideline presents updated recommendations for the optimal management of HBV infection, and future treatment strategies to achieve 'cure' of disease and new biomarkers are discussed.
Journal ArticleDOI
Hepatitis B virus infection [1] (multiple letters)
Journal ArticleDOI
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
Norah A. Terrault,Anna S. Lok,Brian J. McMahon,Kyong-Mi Chang,Jessica P. Hwang,Maureen M. Jonas,Robert S. Brown,Natalie Bzowej,John B. Wong +8 more
TL;DR: This AASLD 2018 Hepatitis B Guidance provides a data-supported approach to screening, prevention, diagnosis, and clinical management of patients with hepatitis B.
Journal ArticleDOI
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.
Shiv Kumar Sarin,Manoj Kumar,George K. K. Lau,Zaigham Abbas,Henry Lik-Yuen Chan,Chien-Jen Chen,Ding-Shinn Chen,Huey-Ling Chen,Pei-Jer Chen,Rong-Nan Chien,Abdul Kadir Dokmeci,Edward Gane,J L Hou,Wasim Jafri,Jidong Jia,J. H. Kim,Ching-Lung Lai,Hon Cheung Lee,Seng Gee Lim,Chun-Jen Liu,Stephen Locarnini,M. Al Mahtab,Rosmawati Mohamed,Masao Omata,Jun Yong Park,Teerha Piratvisuth,Barjesh Chander Sharma,Jose D. Sollano,Fu-Sheng Wang,Lai Wei,Man-Fung Yuen,Shusen Zheng,Jia-Horng Kao +32 more
TL;DR: The final clinical practice guidelines and recommendations for the optimal management of chronic HBV infection are presented here, along with the relevant background information.
Journal ArticleDOI
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
Patrick Marcellin,Edward Gane,Maria Buti,Nezam H. Afdhal,William Sievert,Ira M. Jacobson,Mary Kay Washington,George Germanidis,John F. Flaherty,Raul Aguilar Schall,Jeffrey D. Bornstein,Kathryn M. Kitrinos,G. Mani Subramanian,John G. McHutchison,E. Jenny Heathcote +14 more
TL;DR: In patients with chronic HBV infection, up to 5 years of treatment with tenofovir DF was safe and effective, and long-term suppression of HBV can lead to regression of fibrosis and cirrhosis.